NCT06224725View on ClinicalTrials.gov

Acrylamide and Health Outcomes

CompletedOBSERVATIONAL
Enrollment

1,700

Participants

Timeline

Start Date

January 1, 2004

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
DementiaDementia AlzheimersParkinson DiseaseMyocardial Infarction
Interventions
OTHER

dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)

Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.

Trial Locations (1)

17177

Karolinska Institutet, Stockholm

All Listed Sponsors
collaborator

Stockholm University

OTHER

lead

Karolinska Institutet

OTHER

NCT06224725 - Acrylamide and Health Outcomes | Biotech Hunter | Biotech Hunter